WO1995004520A1 - Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection - Google Patents

Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection Download PDF

Info

Publication number
WO1995004520A1
WO1995004520A1 PCT/US1994/008944 US9408944W WO9504520A1 WO 1995004520 A1 WO1995004520 A1 WO 1995004520A1 US 9408944 W US9408944 W US 9408944W WO 9504520 A1 WO9504520 A1 WO 9504520A1
Authority
WO
WIPO (PCT)
Prior art keywords
epidermal
preparation
steroidal anti
inflammatory agent
chlorhexidine
Prior art date
Application number
PCT/US1994/008944
Other languages
French (fr)
Inventor
William J. Embro
Original Assignee
Embro William J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Embro William J filed Critical Embro William J
Priority to EP94924605A priority Critical patent/EP0664695A1/en
Priority to JP7506565A priority patent/JPH08505402A/en
Publication of WO1995004520A1 publication Critical patent/WO1995004520A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations

Definitions

  • the present invention relates generally to pharmaceutical preparations for the treatment of muco-epidermal and epidermal tissue. More particularly, the present invention relates to gels, creams, solutions and other topical preparations including a mixture of chlorhexidine and at least one non-steroidal anti-inflammatory agent. The invention further provides a method for the treatment of muco-epidermal and epidermal tissue using such preparations.
  • chlorhexidine gels, rinses and creams are routinely used to control bacterial infections on mucosal epidermal and epidermal tissue.
  • chlorhexidine gels and rinses are widely used in dentistry for the treatment of periodontal disease.
  • Non-steroidal anti-inflammatory agents such as ibuprofen, ketoprofen and indomethacin have application in the treatment of, for example, inflammatory diseases such as arthritis, general muscle, skeletal and joint pain and menstrual cramps.
  • a pharmaceutical preparation including a combination of chlorhexidine and at least one anti-inflammatory agent which together show a synergistic effect in the treatment of muco-epidermal and epidermal inflammation and infection.
  • the present invention meets the above-stated objects and others that will become readily apparent by providing topical pharmaceutical preparations which include chlorhexidine and at least one non-steroidal anti-inflammatory agent. These active ingredients are incorporated into a gel, cream, solution, rinse or other pharmaceutically acceptable carrier and are applied topically to sites of epidermal and muco-epidermal inflammation, infection or lesion.
  • the preparations which are the subject of the present invention include a non-toxic amount of chlorhexidine and preferably include, as the non-steroidal anti-inflammatory agent, indomethacin, ibuprofen, ketoprofen or other prostaglandin inhibitors.
  • chlorhexidine and a non-steroidal anti-inflammatory agent unexpectedly show a synergistic effect in the treatment of a number of conditions including, periodontal disease, acne, post-radiation therapy, post- chemotherapy therapy, post-surgical therapy, burns and non-specific epidermal and muco-epidermal infections.
  • the present invention is also directed to a method for treating epidermal and muco-epidermal tissue employing the above-described topical preparations.
  • the course of therapy with such preparations generally requires one to three applications per day or is applied on an as needed basis, depending on the severity of the condition.
  • Treatment includes directly applying the topical preparations to the affected site.
  • the-topical pharmaceutical preparations of the present invention include chlorhexidine in a therapeutically effective amount. For most therapies, from about 0.1 wt.% to about 1.0 wt.%, preferably about 0.2 wt.% of chlorhexidine, has been found to be effective.
  • the preparations further include a non-toxic amount of at least one non-steroidal anti- inflammatory agent, most preferably indocin, ibuprofen and/or ketoprofen, in an amount ranging from about 2 wt.% to about 5 wt.% of the total preparation.
  • the active ingredients are incorporated into a solution, cream, rinse, lotion, gel or other acceptable carrier.
  • the active ingredients are first solubilized and then incorporated into the carrier.
  • a suspending agent such as, for example, acacia powder, xanthan gum, methylcellulose, hydroxymethylcellulose or hydroxypropylcellulose, has been found to be particularly useful when compounding the carrier.
  • hydroxymethylcellulose gel is the preferred carrier where treatment requires manual application of the preparation to affected epidermal or muco-epidermal tissue.
  • Example II Two surgical patients were instructed to apply the preparation described in Example I to post surgical sites twice a day for seven days. In both cases pain, inflammation and infection at the affected sites were relieved.
  • Example II Three patients exhibiting acne sores were instructed to apply the preparation described in Example I to the affected sites twice a day for seven days. In all cases, treatment with the preparations provided a reduction in the pain and inflammation associated with the sores.
  • Example I One patient undergoing radiation therapy and two patients undergoing chemotherapy were each instructed to apply the preparation described in Example I twice daily for one week. All three patients received relief from pain and showed faster healing rates of intraoral tissues following treatment with the prescribed preparations.

Abstract

A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue is provided. The composition includes a therapeutic amount of chlorexidine and at least one non-steroidal anti-inflammatory agent. A method for treating epidermal and muco-epidermal pain, inflammation, infection and lesion by applying the topical preparation directly to the affected site is also provided.

Description

METHOD AND COMPOSITION FOR TREAΗNG MUCO-EPIDERMAL AND
EPIDERMAL PAIN. INFLAMMATION AND INFECTION
BACKGROUND OF THE INVENTION
The present invention relates generally to pharmaceutical preparations for the treatment of muco-epidermal and epidermal tissue. More particularly, the present invention relates to gels, creams, solutions and other topical preparations including a mixture of chlorhexidine and at least one non-steroidal anti-inflammatory agent. The invention further provides a method for the treatment of muco-epidermal and epidermal tissue using such preparations.
The antimicrobial effects of chlorhexidine are well-documented. Chlorhexidine gels, rinses and creams are routinely used to control bacterial infections on mucosal epidermal and epidermal tissue. For example, chlorhexidine gels and rinses are widely used in dentistry for the treatment of periodontal disease. Non-steroidal anti-inflammatory agents such as ibuprofen, ketoprofen and indomethacin have application in the treatment of, for example, inflammatory diseases such as arthritis, general muscle, skeletal and joint pain and menstrual cramps.
While these compounds have been widely used individually by physicians and dentists in the above-described manner for many years, the effectiveness of a combination of chlorhexidine and a non-steroidal anti- inflammatory agent has not been appreciated.
Accordingly, it is the object of the present invention to provide a pharmaceutical preparation including a combination of chlorhexidine and at least one anti-inflammatory agent which together show a synergistic effect in the treatment of muco-epidermal and epidermal inflammation and infection.
It is a further object of the invention to provide a method for treating muco-epidermal and epidermal tissue using such preparations.
SUMMARY OF THE INVENTION
The present invention meets the above-stated objects and others that will become readily apparent by providing topical pharmaceutical preparations which include chlorhexidine and at least one non-steroidal anti-inflammatory agent. These active ingredients are incorporated into a gel, cream, solution, rinse or other pharmaceutically acceptable carrier and are applied topically to sites of epidermal and muco-epidermal inflammation, infection or lesion. The preparations which are the subject of the present invention include a non-toxic amount of chlorhexidine and preferably include, as the non-steroidal anti-inflammatory agent, indomethacin, ibuprofen, ketoprofen or other prostaglandin inhibitors.
As demonstrated below by the various examples provided, the combination of chlorhexidine and a non-steroidal anti-inflammatory agent unexpectedly show a synergistic effect in the treatment of a number of conditions including, periodontal disease, acne, post-radiation therapy, post- chemotherapy therapy, post-surgical therapy, burns and non-specific epidermal and muco-epidermal infections.
The present invention is also directed to a method for treating epidermal and muco-epidermal tissue employing the above-described topical preparations. The course of therapy with such preparations generally requires one to three applications per day or is applied on an as needed basis, depending on the severity of the condition. Treatment includes directly applying the topical preparations to the affected site.
DETAILED DESCRIPTION OF THE INVENTION
As noted above, the-topical pharmaceutical preparations of the present invention include chlorhexidine in a therapeutically effective amount. For most therapies, from about 0.1 wt.% to about 1.0 wt.%, preferably about 0.2 wt.% of chlorhexidine, has been found to be effective. The preparations further include a non-toxic amount of at least one non-steroidal anti- inflammatory agent, most preferably indocin, ibuprofen and/or ketoprofen, in an amount ranging from about 2 wt.% to about 5 wt.% of the total preparation.
The active ingredients are incorporated into a solution, cream, rinse, lotion, gel or other acceptable carrier. In some instances, depending upon the particular carrier, the active ingredients are first solubilized and then incorporated into the carrier. The addition of a suspending agent to the carrier such as, for example, acacia powder, xanthan gum, methylcellulose, hydroxymethylcellulose or hydroxypropylcellulose, has been found to be particularly useful when compounding the carrier. In this regard, hydroxymethylcellulose gel is the preferred carrier where treatment requires manual application of the preparation to affected epidermal or muco-epidermal tissue.
Example I
Ten patients exhibiting advanced periodontal disease were treated with a preparation of 0.2% chlorhexidine and 2% ketoprofen incorporated into a hydroxymethylcellulose gel. The patients were each instructed to apply one of the preparations to the affected gums with a tooth brush twice a day for a week. All of these patients experienced relief from pain, infection and inflammation after the prescribed course of therapy.
Example π
Two surgical patients were instructed to apply the preparation described in Example I to post surgical sites twice a day for seven days. In both cases pain, inflammation and infection at the affected sites were relieved.
Example HI
Three patients exhibiting acne sores were instructed to apply the preparation described in Example I to the affected sites twice a day for seven days. In all cases, treatment with the preparations provided a reduction in the pain and inflammation associated with the sores.
Example IV
One patient undergoing radiation therapy and two patients undergoing chemotherapy were each instructed to apply the preparation described in Example I twice daily for one week. All three patients received relief from pain and showed faster healing rates of intraoral tissues following treatment with the prescribed preparations.
While preferred embodiments have been shown and described, various modifications and substitutions may be made without departing from the spirit and scope of the invention. For example, those skilled in the art will recognize that related derivatives of the active ingredients, such as pharmaceutically acceptable salts of chlorhexidine, and other prostaglandin inhibitors, such as flurbiprofen and naproxen, are useful in practicing the present invention

Claims

I Claim:
1. A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue comprising a therapeutic amount of chlorhexidine and a non-toxic amount of at least one non-steroidal anti- inflammatory agent.
2. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is a prostaglandin inhibitor.
3. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is a prostaglandin inhibitor selected from the group consisting of indocin, ibuprofen, ketoprofen, flurbiprofen, naproxen and mixtures thereof.
4. The topical preparation of claim 1 wherein chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% of the total preparation.
5. The topical preparation of claim 1 wherein the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 wt.% to about 5 wt.% of the total preparation.
6. The topical preparation of claim 1 wherein the preparation further comprises a pharmaceutical carrier incorporating the chlorhexidine and the non-steroidal anti-inflammatory agent.
7. The topical preparation of claim 6 wherein the carrier is selected from the group consisting of a solution, cream, rinse, lotion and gel.
8. A topical pharmaceutical preparation for the treatment of epidermal and muco-epidermal tissue comprising a therapeutic amount of chlorhexidine and at least one non-steroidal anti-inflammatory agent selected from the group consisting of indocin, ibuprofen, ketoprofen and mixtures thereof incorporated into a pharmaceutical carrier.
9. The topical preparation of claim 8 wherein the chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% and the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 to about 5 wt.%.
10. The topical pharmaceutical preparation of claim 9 wherein the carrier is a gel.
11. A method for the treatment of epidermal and muco-epidermal tissue, said method comprising the steps of: providing a topical pharmaceutical preparation including a carrier incorporating a therapeutic amount of chlorhexidine and a non-toxic amount of at least one non-steroidal anti-inflammatory agent, and applying the preparation directly to epidermal and muco-epidermal tissue having pain, inflammation, infection or lesion associated therewith.
12. The method of claim 11 further characterized in that the non- steroidal anti-inflammatory agent is a prostaglandin inhibitor selected from the group consisting of indocin, ibuprofen, ketoprofen, flurbiprofen, naproxen and mixtures thereof.
13. The method of claim 11 further characterized in that the chlorhexidine is present in an amount ranging from about 0.1 wt.% to about 1.0 wt.% and the non-steroidal anti-inflammatory agent is present in an amount ranging from about 2 to about 5 wt.%.
14. The method of claim 11 further characterized in that the carrier is selected from the group consisting of a solution, cream, rinse, lotion and gel.
PCT/US1994/008944 1993-08-06 1994-08-08 Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection WO1995004520A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP94924605A EP0664695A1 (en) 1993-08-06 1994-08-08 Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection
JP7506565A JPH08505402A (en) 1993-08-06 1994-08-08 Method for treating mucosal epidermal and epidermal pain, inflammation and infectious disease and therapeutic composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10328993A 1993-08-06 1993-08-06
US08/103,289 1993-08-06

Publications (1)

Publication Number Publication Date
WO1995004520A1 true WO1995004520A1 (en) 1995-02-16

Family

ID=22294404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/008944 WO1995004520A1 (en) 1993-08-06 1994-08-08 Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection

Country Status (4)

Country Link
EP (1) EP0664695A1 (en)
JP (1) JPH08505402A (en)
CA (1) CA2146547A1 (en)
WO (1) WO1995004520A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015165A1 (en) * 1997-09-22 1999-04-01 Biocontrol Incorporated Topical non-steroidal anti-inflammatory drug composition
WO2002064127A1 (en) * 2001-02-15 2002-08-22 Biointeractions Ltd Methods and clinical devices for the inhibition or prevention of mammalian cell growth
FR2822070A1 (en) * 2001-03-15 2002-09-20 Andre Salkin Treatment of adolescence associated skin disorders, e.g. acne or inflammatory lesions, using cosmetic or pharmaceutical composition containing low concentrations of biguanide and pyrimidine compounds
US7771743B1 (en) 1999-05-01 2010-08-10 Biointeractions, Ltd. Infection resistant polymers, their preparation and uses
RU2491061C2 (en) * 2011-12-05 2013-08-27 Елена Николаевна Светлакова Agent for local treatment of periodontal diseases
EP2698149A1 (en) 2012-08-17 2014-02-19 Sanovel Ilac Sanayi ve Ticaret A.S. Topical Aqueous Pharmaceutical Compositions of Flurbiprofen and Chlorhexidine
US8865198B2 (en) 2010-10-25 2014-10-21 Dexcel Pharma Technologies Ltd. Method for treating a periodontal disease

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812192B1 (en) * 2000-07-28 2003-01-31 Oreal USE OF PROSTAGLANDIN EP-3 RECEPTOR ANTAGONISTS AS A COSMETIC AGENT FOR MITIGATING, REDUCING OR STOPPING HAIR AND HAIR LOSS
FR2812190B1 (en) * 2000-07-28 2003-01-31 Oreal USE OF NON-PROSTANOIC AGONISTS OF EP-2 AND / OR EP-4 PROSTAGLANDIN RECEPTORS AS A COSMETIC AGENT FOR MITIGATING, DECREASING OR STOPPING HAIR AND HAIR LOSS

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740365A (en) * 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US4767751A (en) * 1984-01-25 1988-08-30 Beecham Group P.L.C. Topical drug release system
US4789667A (en) * 1984-09-03 1988-12-06 Teijin Limited External pharmaceutical composition and methods of use
US4814176A (en) * 1985-01-11 1989-03-21 Teijin Ltd. Sustained release preparation
US4906670A (en) * 1986-03-25 1990-03-06 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition for the treatment of periodontal disease
US4975271A (en) * 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5230895A (en) * 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767751A (en) * 1984-01-25 1988-08-30 Beecham Group P.L.C. Topical drug release system
US4740365A (en) * 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US4789667A (en) * 1984-09-03 1988-12-06 Teijin Limited External pharmaceutical composition and methods of use
US4814176A (en) * 1985-01-11 1989-03-21 Teijin Ltd. Sustained release preparation
US4906670A (en) * 1986-03-25 1990-03-06 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition for the treatment of periodontal disease
US4975271A (en) * 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
US5230895A (en) * 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015165A1 (en) * 1997-09-22 1999-04-01 Biocontrol Incorporated Topical non-steroidal anti-inflammatory drug composition
US7771743B1 (en) 1999-05-01 2010-08-10 Biointeractions, Ltd. Infection resistant polymers, their preparation and uses
WO2002064127A1 (en) * 2001-02-15 2002-08-22 Biointeractions Ltd Methods and clinical devices for the inhibition or prevention of mammalian cell growth
US6929818B2 (en) 2001-02-15 2005-08-16 Biointeractions Ltd. Methods and clinical devices for the inhibition or prevention of mammalian cell growth
FR2822070A1 (en) * 2001-03-15 2002-09-20 Andre Salkin Treatment of adolescence associated skin disorders, e.g. acne or inflammatory lesions, using cosmetic or pharmaceutical composition containing low concentrations of biguanide and pyrimidine compounds
EP1247521A1 (en) * 2001-03-15 2002-10-09 André Salkin Use of biguanide and pyrimidine derivatives for the preparation of a topical skin care composition
US8865198B2 (en) 2010-10-25 2014-10-21 Dexcel Pharma Technologies Ltd. Method for treating a periodontal disease
US9278064B2 (en) 2010-10-25 2016-03-08 Dexcel Pharma Technologies Ltd. Method for treating a periodontal disease
US9889090B2 (en) 2010-10-25 2018-02-13 Dexcel Pharma Technologies Ltd. Method for treating a periodontal disease
RU2491061C2 (en) * 2011-12-05 2013-08-27 Елена Николаевна Светлакова Agent for local treatment of periodontal diseases
EP2698149A1 (en) 2012-08-17 2014-02-19 Sanovel Ilac Sanayi ve Ticaret A.S. Topical Aqueous Pharmaceutical Compositions of Flurbiprofen and Chlorhexidine
WO2014027976A1 (en) 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Topical aqueous pharmaceutical compositions of flurbiprofen and chlorhexidine
EP2865370A1 (en) 2012-08-17 2015-04-29 Sanovel Ilac Sanayi ve Ticaret A.S. Topical aqueous pharmaceutical compositions of flurbiprofen and chlorhexidine
EP3834815A1 (en) 2012-08-17 2021-06-16 Sanovel Ilac Sanayi Ve Ticaret A.S. Topical aqueous pharmaceutical compositions of flurbiprofen and chlorhexidine

Also Published As

Publication number Publication date
CA2146547A1 (en) 1995-02-16
EP0664695A1 (en) 1995-08-02
JPH08505402A (en) 1996-06-11

Similar Documents

Publication Publication Date Title
AU777821B2 (en) Therapeutic compositions and methods of use thereof
AU609090B2 (en) Composition for treatment of acne
JP2007513162A (en) Compositions and methods for topical treatment of skin infections
WO2009106963A2 (en) Dental composition for preventing and treating stomatitis and mouth ulcers
WO2003103691A1 (en) Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
CA2141056C (en) Treatment of dentoalveolar infections with taurolidine and/or taurultam
WO1995004520A1 (en) Method and composition for treating muco-epidermal and epidermal pain, inflammation and infection
EP0988040A1 (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
US4518583A (en) Hemorrhoid and anorectal disease treatment method
RU2184538C2 (en) Use of dichlorobenzyl alcohol for preparing medicinal agent for treatment of topical inflammation and medicinal agent comprising dichlorobenzyl alcohol
JP2983335B2 (en) Use of fosfomycin and its pharmaceutically acceptable salts as topical scar forming agents
US4985235A (en) Treatment of periodontoclasia with retinoic acid
JPS6054932B2 (en) therapeutic composition
WO1983000628A1 (en) A method of treating acne vulgaris and composition containing carbamide peroxide
US4879106A (en) Methods for treating gingivitis and paradental pyorrhea
EP0228137B1 (en) Anaerobe-selective antibacterial compositions
JPH07247210A (en) Composition for oral cavity
EP0353675B1 (en) Treatment of periodontoclasia with retinoic acid
JPH0637383B2 (en) Oral anti-inflammatory agent
RU2628880C1 (en) Method for treatment of fast progressing periodontitis (fpp)
UA137242U (en) GEL FOR THE TREATMENT OF DYSTROPHIC-INFLAMMATORY DISEASES OF PERIODONT AND TRAUMATIC LESIONS OF THE ORAL MUCOUS
WO1987003476A1 (en) Composition for the treatment of periodontal disease
CA2379653A1 (en) Pharmaceutical composition for topical application, uses and process for the preparation thereof
RU2137461C1 (en) Composition for treatment of mouth cavity sicknesses
WO1998027968A1 (en) Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2146547

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994924605

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1994924605

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994924605

Country of ref document: EP